Review
Copyright ©The Author(s) 2018.
World J Gastroenterol. Dec 28, 2018; 24(48): 5418-5432
Published online Dec 28, 2018. doi: 10.3748/wjg.v24.i48.5418
Table 2 Current clinical vaccination studies including colorectal cancer patients
Target typeTarget moleculeVaccination strategyTherapyNumber of patientsTrial identifier
TAACEAalphavirus replicon (VRP) encoding CEA12NCT01890213
TAACEAETBX-011 ad-CEA, ALT-803 (IL-15)3NCT03127098
TAACEAanti-CEA CAR-T cells18NCT03682744
TAACEAanti-CEA CAR-T cells5NCT02850536
TAACEAanti-CEA CAR-T cells, SIR-Sphere8NCT02416466
TAAHer22 Her2 peptides in Montanide ISA 72036NCT01376505
TAAHer2/neuB-Cell and monocytes with HER2/neu antigen9NCT03425773
TAABrachyury, CEA, MUC1ETBX-051; adenoviral brachyury vaccine, ETBX-061; adenoviral MUC1 vaccine, ETBX-011; adenoviral CEA vaccine32NCT03384316
TAA7 cancer testis antigens6 synthetic peptides in MontanideStandard-of care maintenance15NCT03391232
Immune stimulation, TAAMUC1activated CIK and CD3-MUC1 bispecific antibodycryotherapy90NCT03524274
TAAHPVDPX-E744NCT02865135
TAAhTERTINO-1400 or INO-1401 alone or in combination with INO-901293NCT02960594
TAAMUC1anti-MUC1 CAR-pNK cells10NCT02839954
TAAMUC1MUC1 peptide-poly-ICLC110NCT02134925
TAAEpCAMCAR T Cells targeting EpCAM60NCT03013712
Immune checkpoint, TAAPD-1, p53Pembrolizumab, modified vaccinia virus Ankara vaccine expressing p5319NCT02432963
Neoantigenframeshift-derived neoantigen-loaded DC25NCT01885702
Neoantigenpersonalized neoepitope yeast-based vaccine, YE-NEO-00116NCT03552718
NeoantigenmRNA-based vaccine targeting neoantigens64NCT03480152
NeoantigenADXS-NEO (Advaxis NEO expressing personalized tumor antigens)48NCT03265080
Neoantigenrasanti-KRAS G12 V mTCRCyclophosphamide, Fludarabine, Aldesleukin110NCT03190941
Immune checkpointPD-L1Avelumab, autologous dendritic cells33NCT03152565
Immune checkpointPD-1Pembrolizumab, GVAX (allogeneic colon cancer GM-CSF secreting cells)Cyclophosphamide17NCT02981524
Immune checkpointPD-L1Atezolizumab, Imprime PGG (PAMP recognized by innate immune effector cells)Regorafenib/ Isatuximab/ Bevacizumab120NCT03555149
Immune checkpointA2aR, A2bRAB928 (A2aR and A2bR antagonist)FOLFOX98NCT03720678
Immune checkpoint, TAAPD-1, CEA, MUC-1Nivolumab, MVA-BN-CV301 (modified vaccinia Ankara-Bavarian Nordic encoding CEA, MUC1, B7-1, ICAM-1 and LFA-3)FOLFOX78NCT03547999
Immune checkpoint, TAAPD-L1Atezolizumab, RO7198457 (mRNA-based individualized, TAAs vaccine)567NCT03289962
Immune checkpoint, TAAPD-L1, CEAAvelumab + Ad-CEAFOLFOX, Bevacizumab, Capecitabine81NCT03050814
Immune checkpoint, TAA, Immune stimulationCEA, Her2/neu, Brachyury, MUC1, RAS, NK cells ICIAldoxorubicin, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, HCI, ALT-803Capecitabine, Cetuximab, Cyclophosphamide, Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT, Trastuzumab332NCT03563157
Immune checkpoint, Mutated proteinsPD-1Personalized peptides, Pembrolizumab60NCT02600949
Immune stimulationGVAX (allogeneic colon cancer GM-CSF secreting cells)Cyclophosphamide, SGI-110 (DNA Methyltransferase Inhibitor)18NCT01966289
Immune stimulationGVAX (allogeneic colon cancer GM-CSF secreting cells)15NCT01952730
Immune stimulationOncoVAX (non-dividing tumor cells)Surgery550NCT02448173
Immune stimulationAutologous or allogeneic immune stimulatory tumor cells50NCT00722228
Immune stimulationautologous dendritic cells loaded with autologous tumour homogenate + IL-219NCT02919644
Immune stimulationautologous dendritic cells loaded with tumor antigens58NCT01348256
Immune stimulationautologous dendritic cells loaded with tumor lysate antigens30NCT03214939
Oncolytic virusGL-ONC1 oncolytic vaccinia virus, which disrupts nonessential genes and expression of the foreign gene expression36NCT02714374
Oncolytic virus, Immune checkpointPD-L1Talimogene Laherparepvec, Atezolizumab36NCT03256344